Glucokinase (hexokinase IV, GK) is the predominant hexokinase expressed in hepatocytes and in pancreatic beta-cells where it functions as the glucose sensor for insulin secretion (1, 2) . It is also expressed in cells of the gut, hypothalamus and anterior pituitary (3) (4) (5) . The role of GK in the control of blood glucose homeostasis is supported by the impact of naturally occurring mutations, which cause either diabetes (GK-MODY and GK-PNDM) or persistent hyperinsulinaemic hypoglycaemia of infancy (PHHI) (1, 6) .
GK is regulated by both transcriptional and post-transcriptional mechanisms (7) . Post-transcriptional regulation differs in hepatocytes and pancreatic β-cells as demonstrated by the different sub-cellular location of GK. In hepatocytes, regulation involves an inhibitory regulatory protein (GKRP) that functions as a nuclear receptor, sequestering GK in an inactive state in the nucleus at low glucose (8) (9) (10) ). An increase in extracellular glucose concentration causes translocation of GK to the cytoplasm, enabling rapid stimulation of glucose phosphorylation. Translocation of GK between the nucleus and the cytoplasm is also dependent on other proteins that function as cytoplasmic receptors or shuttling proteins, such as the bifunctional protein PFK2/FDP2, which catalyses the formation and degradation of fructose 2,6-bisphosphate (11, 12) .
Islet β-cells do not express hepatic GKRP and accordingly GK does not accumulate in the nucleus (5, 10, 13) . Whether they express a truncated form of GKRP lacking the nuclear localising signal (14) is not known. PFK2/FDP2 serves as a GK binding protein in β-cells and has a role in the regulation of GK activity (11, 15, 16) . Additional binding proteins of GK have also been identified in β-cells, including neuronal nitric oxide and others (17) (18) (19) .
To date approximately 200 naturally occurring GK mutations have been identified that cause either diabetes or hypoglycaemia (1, 20) . Detailed kinetic analysis is available for about one fifth of these (20, 21) and whilst in most cases the defective glycaemia can be explained by the enzyme kinetics, some mutations which co-segregate with hyperglycaemia in GK-MODY have near normal enzyme kinetics or even a mild increase in affinity for glucose. Some mutants (H137R, V203A, M298K, S263P, E300K, V367M, C213R) are enzymatically unstable in heat-stability assays (21, 22) , whilst the mutant E300K also showed protein instability when expressed in pancreatic β-HC9 cells using an adenoviral expression system (23) , Two mutants that are of particular interest are V62M and G72R (24, 25) . These mutants segregate with hyperglycaemia in three families but are moderately activating and show only mild thermolability. Both mutants show lack of inhibition by liver GKRP and lack of activation by pharmacological GK activators that bind to the novel allosteric site (26) . Because liver GKRP is not expressed in pancreatic β-cells and no physiological ligands have been identified that mimic the action of pharmacological activators, no explanation is available as yet for the mechanism by which V62M and G72R cause hyperglycaemia.
The aim of this study was to develop a cell-based approach to investigate the activity and expression of GK-MODY mutants, such as V62M and G72R, where the clinical phenotype cannot be explained by the kinetic properties of the enzyme.
EXPERIMENTAL DESIGN AND METHODS
Generation of constructs: Constructs for human wild-type pancreatic β-cell GK were generated with the GFP-tag at either the N-or C-terminus. For generation of N-terminal GFP-tagged GK, GK was excised from the pT73.36His vector (kindly provided by K. Brocklehurst, AstraZeneca, Cheshire, UK) using the BamHI/XhoI restriction sites for ligation into BglII/SalI of the pEGFP-C1 vector (Gibco Invitrogen Co, Paisley, UK). For generation of Cterminal tagged GK, GK was excised from the pT73.36His vector using the BamHI/NotI restriction sites for ligation into the PCR3 vector (Promega, Southampton, UK) with addition of a Cterminal GFP-tag generated by PCR. The mutant constructs GST-V62M and GST-G72R were excised from the pGEX-3X plasmid and inserted into the pEGFP-C3 vector for addition of the Nterminal GFP tag as above. Correct insertion into the plasmids was confirmed by DNA sequencing.
Cell culture and treatment with adenoviral vectors. MIN6 cells (p20-27) were cultured in Dulbecco's modified Eagle's medium containing 15% (vol/vol) fetal bovine serum. Adenoviral vectors for expression of untagged GK (Ad-LGK), GKRP (Ad-GKRP) and PFK2/FDP2 (Ad-PFK2/FDP2) were described previously (27, 28, 29) . MIN6 monolayers were incubated with the adenoviral vectors for 4-6 h and then cultured for 24-48 h to allow protein expression.
Transfection and generation of stable cell lines. For transient transfection, MIN6 were transfected with 1-3µg plasmid DNA and 1-3µl Lipofectamine 2000 for 8h and then cultured for 24-48h. Stable cell lines were generated after transient transfection by selection with 300µg/ml G418 for 3-4 weeks. For non-clonal cell lines (GFP-GK and GK-GFP), the cells were cultured in G418-containing medium. For clonal cell lines (GFP-GK, GFP-V62M and GFP-G72R), clones were isolated and expanded in the presence of 300µg/ml G418.
Clones with appropriate expression of GFP-GK were selected for further study based on GK activity, immunoreactivity and human GK mRNA expression. The clones used in this study were WT3B and WT10B for GFP-GK, V62M 3C for GFP-V62M and G72R 25A for GFP-G72R. For transient transfection of hepatocytes, freshly isolated rat hepatocytes (30) were transfected 3h after attachment with 4µg plasmid DNA and 12µl jet-PEI-Gal (Qbiogene) and cultured for 24h.
GK activity, GK immunoreactivity and GK kinetics. GK activity of MIN6 and GFP-tagged GK cell lines was determined on 13,000g supernatants as described in (31) . Glucose phosphorylating activity was determined at 0.5mmol/l and 50mmol/l glucose, representing low-K m and total hexokinase activity, respectively and GK activity determined from the difference between total hexokinases and low K m hexokinases. GK immunoreactivity was determined by SDS-PAGE and immunoblotting with a GK antibody (H-88 Santa Cruz Biotech, Santa Cruz, CA) as described previously (31) . For kinetic analysis, GK activity was determined at the indicated concentrations of glucose and a GKA (GKA1, ref (32), a gift from M. Coghlan, AstraZeneca, Cheshire, UK). The S 0.5 for glucose was determined from Hill plots.
Real time RT-PCR. Cellular RNA was extracted using TRIzol (Invitrogen) and treated with DNaseI (Roche, East Sussex, UK). Single strand cDNA was synthesized from 1µg of total RNA with random hexamers and Superscript II (Invitrogen). Real-time RT-PCR was performed in a total volume of 10µl containing 20ng of reverse transcribed total RNA for determination of murine GK, human GK and cyclophilin, 5µmol/l primers (Murine GK: forward 5'-GCA GAA GGG AAC AAC ATC GT, reverse 5'-CAC ATT CTG CAT CTC CTC CA; Human GK: forward 5'-ATC TCC GAC TTC CTG GAC AA, reverse 5'-CAC TCG GTA TTG ACG CAC AT; Cyclophilin: forward 5'-ATG GCA CTG GTG GCA AGT CC -3', reverse 5'-TTG CCA TTC CTG GAC CCA AA -3' (33)), 2mmol/l MgCl 2 and 1µl Sybr Green (Roche). The reactions were carried out in capillaries in a Light Cycler (Roche) with initial denaturation at 95°C for 10min followed by 40 cycles consisting of 95°C for 15sec, 58°C for 7sec and 72°C for 15sec. Murine and human GK mRNA were expressed relative to cyclophilin mRNA and as percentage of control.
Isolation of mouse pancreatic islets. Pancreatic islets were isolated from male C57/BL6 mice. The pancreas was shaken with 1.5mg/ml liberase (Roche) for 6 min, with further digestion with 0.75mg/ml liberase for 2-6min. Overdigestion was prevented by washing in Krebs-Ringer Phosphate Buffer (10mmol/l Hepes (pH 7.4), 90mmol/l NaCl, 5mmol/l NaHCO 3 , 4.8mmol/l KCl, 0.7mmol/l KH 2 PO 4 , 0.6mmol/l, MgSO 4 2.5mmol/l 1M CaCl 2 , 0.1% BSA, 5.5mmol/l glucose). Islets were picked and cultured overnight in RPMI.
Insulin secretion. MIN6 monolayers were cultured in 24-well plates and washed with Krebs-Ringer buffer (34). They were preincubated for 30 min in glucose-free Krebs Ringer buffer followed by 1 h incubation at the indicated concentrations of glucose and a GKA (35), a gift from J. McCormack, OSI Prosidion, Oxford, UK). After overnight culture, islets were preincubated with Krebs Ringer Phosphate buffer (3 islets/200 µl) at 3 mmol/l glucose for 30 min, followed by 2h at the indicated concentrations of glucose and GKA.
Medium insulin was determined using a rat insulin assay kit (Mercodia, Uppsala, Sweden)
Microscopy.
Cells cultured on coverslips were washed with PBS and fixed using 4% paraformaldehyde in PBS. Immunostaining for endogenous GK and insulin was as described previously (31) . Cells were visualised using a Leica TCS-SP2-UV microscope with an x63, NA 1.3 oil immersion objective or a LSM Zeiss microscope with an x63 1.4 oil immersion objective.
Statistical Analysis.
This was by ANOVA followed by the Bonferroni test using the Prism analysis program.
RESULTS
GFP-tagged GK is catalytically active when expressed in MIN6. Transient transfection of MIN6 with GK tagged with GFP at either the N-terminus or Cterminus, was associated with immunoreactivity to GK at 62-64 kDa as expected, and with a 7-10 fold increase in GK activity, confirming that GFPtagged GK is catalytically active (Fig.  1A) . Because, fluorescence microscopy showed large intercellular heterogeneity in GFP expression after transient transfection we generated stable nonclonal cell lines by G418 selection. GK activity conferred by GFP-tagged GK was stable during early passages (< p9) but declined in later passages (Fig. 1B) . Likewise human GK-mRNA decreased with progressive passage (5-8 fold between p9 and p19). Expression of endogenous (mouse) GK mRNA was similar in the GK-GFP and GFP-GK cell lines (125% and 93%) as in nontransfected MIN6. The affinity of GK for glucose (mmol/l) was similar in extracts of GK-GFP and GFP-GK cells (8.9 ± 0.3 and 8.9 ± 0.8) as in MIN6 overexpressing untagged GK with an adenoviral vector (8.5 ± 0.6) and was similarly increased by a GKA (32) in the cell lines (2.3 ± 0.3 and 2.1 ± 0.1) as in the untransfected MIN6 (2.8 ± 0.3) indicating that the GFP tag does not compromise affinity for glucose or activation by a GKA.
Effects of GK activation and overexpression on insulin secretion. Glucose-induced insulin secretion was similar in GK-GFP and GFP-GK cell lines as in untransfected early passage MIN6 ( Fig. 2A) . Insulin secretion in β-cells is dependent on GK activity (36) and on the differentiated state, which in MIN6 declines with passage (37) . Clonal cell lines transfected with GFP alone were considered an inappropriate control because they showed a greater increase in low-K m hexokinase with increasing passage than the GFP-GK cell lines indicating greater dedifferentiation (results not shown). Conversely, untransfected early passage MIN6 may represent a more differentiated state than the GFP-GK cell lines, which could explain the similar glucose-induced insulin secretion ( Fig. 2A) . To investigate the effect of GK activity and concentration on insulin secretion independently of passage number or the differentiated state of MIN6, we compared the effect of titrated adenoviral overexpression of untagged GK with pharmacological GK activation. Whereas GK overexpression had little effect on insulin secretion irrespective of the glucose concentration ( Fig. 2A) , the GKA caused a large stimulation at 3 mmol/l glucose (Fig.2B) . Similar results were obtained when insulin secretion was determined in mouse islets. The GKA caused a 2.6 fold stimulation (P < 0.01) whereas GK overexpression (confirmed by immunoblotting) had no significant effect (Fig. 2C) .
Subcellular location of GFP-tagged GK chimeras in MIN6 and hepatocytes. Co-localisation of GK with insulin granules in pancreatic β-cells has been shown by immunofluorescence microscopy ( (38-41), Fig 3A) , electron microscopy (38, 41) and subcellular fractionation (31) .
To determine whether GFP-tagged GK colocalises with insulin granules, GFP-GK cell lines and MIN6 cells transiently transfected with GFP-GK were stained for insulin (red) and visualised by confocal microscopy. Endogenous GK showed clear co-localisation with endogenous insulin (Fig. 3A) whereas GFP-GK expressed transiently showed negligible co-localisation (Fig. 3B ) and stably expressed GFP-GK showed partial colocalisation with insulin (Fig. 3C) . When the GK-GFP and GFP-GK constructs were transiently transfected into hepatocytes, both proteins accumulated in the nucleus during incubation with 5 mmol/l glucose (results not shown) indicating that the GFP tag does not interfere with binding to nuclear GKRP, in agreement with previous findings with an N-terminal GFP-tag (42) .
Effect of MG132 on expression of GFPtagged GK chimeras.
We tested whether the decrease in transgene expression in late passages could be prevented by inhibition of proteosomal degradation using MG132. MG132 had no effect in either untransfected MIN6 or MIN6 overexpressing untagged GK but it increased GK activity and immunoreactivity (64kDa) in the GK-GFP cell lines (Fig. 4A) . To test whether this increase in GK activity and immunoreactivity was due to inhibition of protein degradation, we determined the effect of MG132 in the presence of cycloheximide to inhibit protein synthesis.
Although GK activity decreased in the presence of cycloheximide, this decrease was not prevented by MG132, excluding an effect on protein degradation (Fig. 4B) . MG132 caused a large increase in human GK-mRNA in the GFP-GK cell lines (100-200 fold, Fig 6A below) . This was abolished by the transcriptional inhibitor, actinomycin D (Fig. 4C) , indicating that MG132 increased transgene expression. MG132 was used in the rest of the study to increase transgene expression.
Pharmacological activation of GK. Previous enzyme kinetic studies on purified GST-GK fusion proteins showed that V62M and G72R mutants have a lower S 0.5 for glucose than wildtype GK and were not activated by a GKA (24, 25) .
We determined the affinity for glucose of GFP-V62M and GFP-G72R in cell extracts of the clonal cell lines pre-cultured with MG132 (see above). Both mutants had a lower S 0.5 for glucose than wild-type (wild-type, 9.0 ± 1.0; V62M 5.2 ± 0.4; G72R 4.6 ± 1.0 mmol/l) and neither was significantly activated by the GKA (32) (Fig. 5A-C) . There was no effect of MG132 on the affinity for glucose (Fig.  5D ).
GK activity and immunoreactivity of GFP-V62M and GFP-G72R in clonal cell lines. The catalytic activity and GK immunoreactivity of the mutants were determined in the clonal cell lines GFP-V62M and GFP-G72R and compared with two clonal cell lines expressing wildtype GFP-GK (WT3B, WT10B). GK activity, immunoreactivity and mRNA were determined after preculture without or with MG132, which caused a large increase in transgene mRNA, GK protein and activity ( Fig.   6A-C) . GFP-V62M and GFP-G72R had a lower GK activity than the wild-type clones when expressed relative to either immunoreactivity or mRNA (Fig. 6D-E) . There was no significant difference in GK immunoreactivity relative to mRNA levels for either mutant compared with wild-type clones suggesting instability of catalytic activity but not immunoreactive protein.
Transient transfection studies with GFP-V62M and GFP-G72R. The activity/immunoreactivity ratio was also determined after transient transfection of MIN6 with varying plasmid amounts of GFP-GK (wild-type), GFP-V62M and GFP-G72R (Fig. 7A-B) . Plots of GK activity against immunoreactivity showed a lower activity / immunoreactivity ratio for both GFP-V62M and GFP-G72R compared with wild-type GFP-GK (Fig. 7C ) consistent with the findings from the clonal cell lines. The effect of the GKA (35) on insulin secretion was determined in MIN6 that were either untransfected or transiently transfected with the GFP-constructs. The GKA increased (P< 0.05) insulin secretion at 5mmol/l glucose in all four conditions tested (untransfected: 1.7 ± 0.2 to 2.7 ± 0.1; GFP-GK, 1.8 to ± 0.1 to 3.6 ± 0.1; GFP-V62M, 1.7 to ± 0.1 to 3.0 ± 0.1; GFP-G72R, 1.5 to ± 0.1 to 3.7 ± 0.2 µg/h per mg protein).
Stabilisation of GK by liver PFK2-FDP2 and GKRP. The GK-binding proteins PFK2/FDP2 and GKRP modulate GK activity in pancreatic β-cells and liver, respectively.
We therefore tested whether the mutants show altered activation or stabilisation when these proteins are heterologously expressed in MIN6 cells. Expression of PFK2/FDP2 using an adenoviral vector in the clonal cell lines increased GK activity in the wild-type clones and in GFP-V62M but not in GFP-G72R or in the non-transfected cells (Fig. 8A) . The lack of effect in the non-transfected cells may be due to a saturating effect of the endogenous PFK2/FDP2 on endogenous GK. Overexpression of the liver GKRP protein resulted in a small but significant increase in GK activity in the wild-type GFP-GK but not in the mutant cell lines or in untransfected MIN6 (Fig. 8B) . Interaction of the mutants with GKRP was also tested by transient transfection of the GFP constructs in hepatocytes. Unlike GFP-GK which accumulated in the nucleus at 5 mmol/l glucose and translocated to the cytoplasm at 25 mmol/l glucose, neither GFP-V62M nor GFP-G72R accumulated in the nucleus at 5 mmol/l glucose (Fig. 8C ).
DISCUSSION
Mutations in the GK gene identified in MODY-2 subjects are associated with a similar phenotype of elevated fasting blood glucose (> 5.5 mmol/l) and a 2-hour increment in blood glucose after an oral glucose tolerance test of ~ 2 mmol/l, irrespective of whether the mutation severely compromises GK kinetics or has negligible effect or is mildly activating (21, 24, 25) . The apparent paradox of elevated blood glucose in MODY2 subjects with mildly activating GK mutations is as yet unexplained. In this study we used MIN6 cells either transiently transfected or stably expressing GFP-GK chimaeras to study the expression of the MODY mutants V62M and G72R, which are mildly activating. The limitations of transient transfection are the intercellular heterogeneity of expression, which necessitates high levels of transgene transfection and also the variability in mRNA and protein expression with time. Conversely, the limitation of cell lines is the progressive loss in differentiated state with increasing passage, which may differ between wild-type and mutant clones. A complementary approach of both transient and stable transfection methods identifies possible artefacts that may be inherent in either technique.
We show in this study that GFPtagged GK expressed either transiently in MIN6 cells or after clonal selection with G418 is catalytically active and shows similar kinetic properties as the untagged enzyme or recombinant GST-GK fusion enzymes (43) . Accordingly, GFP-tagged GK is predicted to be functional when expressed in MIN6. However, although clonal cell lines expressing GFP-tagged GK had increased GK activity, they showed similar glucose-induced insulin secretion as untransfected MIN6. This cannot be attributed to mistargeting of the GFP-tagged GK, because similar results were obtained when untagged GK was overexpressed with the adenoviral vector in MIN6. The latter finding is not a unique property of the MIN6 β-cell model because lack of stimulation of insulin secretion after GK overexpression was also reported in rat islets (27) . In this study we show that in both mouse islets and MIN6 cells there is lack of stimulation of insulin secretion by titrated GK overexpression, despite stimulation by a pharmacological GKA. A tentative explanation is that coupling between GK activity and stimulation of insulin secretion is dependent on subcellular location or targeting through association with binding proteins. Saturation of these receptors by endogenous GK may explain the lack of stimulation of insulin secretion by GK overexpression despite stimulation by the GKA, which mimics the effect of elevated glucose.
We could not detect a difference in subcellular localisation between mutants and wild-type.
It is noteworthy, however, that colocalisation between GK and insulin in MIN6 cells is most clearly observed at endogenous levels of GK (31, 38, 39) . Expression of GFP-GK wild-type resulted in the accumulation of GK in the cytoplasm with partial colocalisation with the insulin granules. This may be explained by saturation of GK binding proteins similar to saturation of GKRP in hepatocytes when GK is overxpressed by 2-fold, which results in a marked decrease in nuclear / cytoplasmic distribution (44) . Although, we could not detect a difference in colocalisation between mutants and wildtype we also cannot unequivocally rule out a difference in targeting.
We show in this study using clonal cell lines expressing mutant (V62M and G72R) or wild-type GFP-GK that the GK activity / immunoreactivity ratio is lower for the mutants than for wild-type GK, despite a similar protein expression based on immunoreactivity / mRNA ratio. The transient transfection experiments in MIN6 also confirmed a lower activity / immunoreactivity ratio for V62M and G72R (60% and 85% decrease in the slope of the linear plots). Two possible mechanisms can be considered for the lower "specific activity" of the mutants. First that GK binding proteins have a positive effect on the wild-type enzyme by either an "activation" mechanism as proposed for PFK/FDP2 or by protecting GK from inactivation by oxidation of thiol groups (45, 46) . Second, that the mutants are more unstable than the wild-type in the cellular environment because their conformation makes them more susceptible to inactivation by oxidation of thiol groups or other mechanisms. The lack of catalytic instability of the mutants when tested in thermal stability assays using the purified recombinant enzyme (24,25, Arden, C and Agius, L, unpublished) argues against the latter possibility.
A role for binding proteins in stabilising GK activity has been clearly demonstrated in liver. Although GKRP was initially identified as an inhibitor and nuclear receptor for GK (8-10) studies on GKRP-/-mice established a major role for this protein in stabilising hepatic GK at the post-transcritpional level (47, 48) . However, less is known about stabilising proteins in pancreatic β-cells. Furthermore, whether MIN6 cells express the full complement of GK binding proteins as pancreatic islets is unknown. The present finding that heterologous expression of the liver protein GKRP in β-cells increased GK activity for GFP-GK wild-type but not V62M or G72R is consistent with the lack of inhibition of catalytic activity of the recombinant mutants by GKRP (24, 25) , but is also indicative of a high catalytic or protein instability of wildtype GK in β-cells. The lack of effect on GK activity of GKRP overexpression in untransfected MIN6 indicates a role for endogenous proteins in β-cells that may have a homologous or analogous function to GKRP.
A role for PFK2/FDP2 in activating GK in β-cells has been demonstrated (11, 15, 16) . In this study expression of PFK2/FDP2 increased GK activity in cells expressing GFP-GK wild-type and GFP-V62M but not in non-transfected cells. This supports a role for the endogenous PFK2/FDP2 in MIN6, which was also confirmed by down-regulation of PFK2/FDP2 by siRNA in MIN6 (C. Arden & L. Agius, unpublished) . The lack of effect of PFK2/FDP2 on GK activity in cells expressing GFP-G72R suggests that this mutation affects the interaction with PFK2/FDP2 and indicates that the decrease in catalytic activity / immunoreactivity for G72R is at least in part explained by lack of activation by PFK2/FDP2.
Although the V62M and G72R mutants are relatively unresponsive to activation by pharmacological GKAs compared with wild-type-GK (24, 25) , insulin secretion in MIN6 cells overexpressing GFP-V62M or GFP-G72R was stimulated by the GKA to a similar extent as in untransfected MIN6 or in cells expressing GFP-GK wildtype. This shows that the mutants do not have a dominant negative effect or attenuate insulin secretion. Accordingly, the explanation for the phenotype of these mutations is the low catalytic activity.
In summary, we show in this study using a cell-based approach that cellular instability of GK catalytic activity in pancreatic β-cells rather than increased mRNA degradation, impaired translation or enhanced protein degradation may be the key factor that accounts for the hyperglycaemia associated with the V62M and G72R mutations.
FIG. 4. Effect of MG132 on expression of GFP-tagged chimeras.
A. GK activity was determined after culture for 18 h without (open) or with (solid) 10µmol/l MG132 in GK-GFP and GFP-GK cells and MIN6 either untreated or treated with Ad-LGK (+GK), n = 7. GK immunoreactivity is representative of 7 experiments. * P < 0.05, ** P < 0.01 effect of MG132. B. Untreated MIN6 and MIN6 transiently transfected with GFP-GK were incubated without (open bars) or with 5µmol/l cycloheximide and without (shaded bars) or with 10 µmol/l MG132 (closed bars) for 4-6h. * P < 0.05 relative to untreated cells, n = 2. C. Clonal cell lines expressing GFP-GK (WT10B) was incubated with 0.4µg/ml actinomycin D (Act D), 10 µmol/l MG132 or both for 3 h, n=2.
